United Therapeutics CEO Martine Rothblatt Sells $5.46 Million of Stock Under Trading Plan
United Therapeutics Chairperson and Chief Executive Martine Rothblatt sold $5.46 million of company stock on Monday, Nov. 9, after exercising stock options, according to two Form 4s filed Tuesday.
Rothblatt exercised 9,500 options at $117.76 a share and sold 9,500 shares through a family trust. The filings list 27 blocks at weighted average prices running from $556.52 to $585.63 a share. The sales totaled $5,459,774, or an average of $574.71 a share.
She split the report across two forms because of the 30-line limit on the table that lists the trades, the filings say.
A prearranged plan
The exercise and sale were made under a Rule 10b5-1 trading plan Rothblatt adopted on Nov. 7, 2025, according to the filing. The plan runs until the earlier of the exercise of 1,734,410 stock options, all expiring March 15, 2027, or Dec. 31, 2026.
What she holds now
After the sales, the trust that made them held 324,443 shares. Rothblatt also reported 40,513 shares held directly, 166 shares held by her spouse and three other family trusts holding 249,108, 45,596 and 8,902 shares.
By the numbers
- Options exercised: 9,500 at $117.76
- Shares sold: 9,500
- Sale value: $5,459,774
- Average sale price: $574.71
- Trade date: Nov. 9, 2026
Sources
- Form 4, Martine A. Rothblatt (first of two filings), United Therapeutics Corporation, filed Nov. 10, 2026, accession 0001106578-26-000184
- Form 4, Martine A. Rothblatt (second of two filings), United Therapeutics Corporation, filed Nov. 10, 2026, accession 0001106578-26-000185
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.